Federal Register
Notice: FDA has determined the regulatory review period for Takeda Pharmaceutical’s Rozerem is 2,224 days for extending a patent which claims the human drug product. Rozerem is indicated for treating insomnia characterized by difficulty with sleep onset. To view this notice, click here.